Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Obstructive Lung Diseases

  Free Subscription


Articles published in Respir Res

Retrieve available abstracts of 132 articles:
HTML format



Single Articles


    November 2021
  1. SVERRILD A, Leadbetter J, Porsbjerg C
    The use of the mannitol test as an outcome measure in asthma intervention studies: a review and practical recommendations.
    Respir Res. 2021;22:287.
    PubMed     Abstract available


    October 2021
  2. HARDING JN, Gross M, Patel V, Potter S, et al
    Association between particulate matter containing EPFRs and neutrophilic asthma through AhR and Th17.
    Respir Res. 2021;22:275.
    PubMed     Abstract available


  3. TUPPER OD, Ulrik CS
    Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma.
    Respir Res. 2021;22:269.
    PubMed     Abstract available


  4. CARSTENSEN S, Gress C, Erpenbeck VJ, Kazani SD, et al
    Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor.
    Respir Res. 2021;22:262.
    PubMed     Abstract available


    September 2021
  5. RYBKA-FRACZEK A, Dabrowska M, Grabczak EM, Bialek-Gosk K, et al
    Does bronchial hyperresponsiveness predict a diagnosis of cough variant asthma in adults with chronic cough: a cohort study.
    Respir Res. 2021;22:252.
    PubMed     Abstract available


  6. PARASARAM V, Wang X, Krisanarungson P, Vyavahare N, et al
    Targeted delivery of pentagalloyl glucose inhibits matrix metalloproteinase activity and preserves elastin in emphysematous lungs.
    Respir Res. 2021;22:249.
    PubMed     Abstract available


  7. KELLERER C, Jorres RA, Schneider A, Alter P, et al
    Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET.
    Respir Res. 2021;22:242.
    PubMed     Abstract available


    August 2021
  8. MITSUNE A, Yamada M, Fujino N, Numakura T, et al
    Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation.
    Respir Res. 2021;22:232.
    PubMed     Abstract available


  9. ZHANG S, Fan Y, Qin L, Fang X, et al
    IL-1beta augments TGF-beta inducing epithelial-mesenchymal transition of epithelial cells and associates with poor pulmonary function improvement in neutrophilic asthmatics.
    Respir Res. 2021;22:216.
    PubMed     Abstract available


    July 2021
  10. TAKEDA K, Kim SH, Joetham A, Petrache I, et al
    Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema.
    Respir Res. 2021;22:207.
    PubMed     Abstract available


  11. WARREN KJ, Poole JA, Sweeter JM, DeVasure JM, et al
    Neutralization of IL-33 modifies the type 2 and type 3 inflammatory signature of viral induced asthma exacerbation.
    Respir Res. 2021;22:206.
    PubMed     Abstract available


  12. O'BEIRNE SL, Salit J, Kaner RJ, Crystal RG, et al
    Up-regulation of ACE2, the SARS-CoV-2 receptor, in asthmatics on maintenance inhaled corticosteroids.
    Respir Res. 2021;22:200.
    PubMed     Abstract available


    June 2021
  13. PAPAKONSTANTINOU E, Koletsa T, Zhou L, Fang L, et al
    Bronchial thermoplasty in asthma: an exploratory histopathological evaluation in distinct asthma endotypes/phenotypes.
    Respir Res. 2021;22:186.
    PubMed     Abstract available


  14. LEMIERE C, Taille C, Lee JK, Smith SG, et al
    Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Respir Res. 2021;22:184.
    PubMed     Abstract available


  15. MO Y, Ye L, Cai H, Zhu G, et al
    SERPINB10 contributes to asthma by inhibiting the apoptosis of allergenic Th2 cells.
    Respir Res. 2021;22:178.
    PubMed     Abstract available


  16. WARDZYNSKA A, Pawelczyk M, Rywaniak J, Makowska J, et al
    Circulating miRNA expression in asthmatics is age-related and associated with clinical asthma parameters, respiratory function and systemic inflammation.
    Respir Res. 2021;22:177.
    PubMed     Abstract available


  17. GIBSON PG, Prazma CM, Chupp GL, Bradford ES, et al
    Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Respir Res. 2021;22:171.
    PubMed     Abstract available


  18. ABDO M, Uddin M, Goldmann T, Marwitz S, et al
    Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma.
    Respir Res. 2021;22:167.
    PubMed     Abstract available


  19. KUROKAWA A, Kondo M, Arimura K, Ashino S, et al
    Less airway inflammation and goblet cell metaplasia in an IL-33-induced asthma model of leptin-deficient obese mice.
    Respir Res. 2021;22:166.
    PubMed     Abstract available


    May 2021
  20. WATSON A, Oberg L, Angermann B, Spalluto CM, et al
    Dysregulation of COVID-19 related gene expression in the COPD lung.
    Respir Res. 2021;22:164.
    PubMed     Abstract available


  21. PADILLA-GALO A, Garcia-Ruiz AJ, Levy Abitbol RC, Olveira C, et al
    Real-life cost-effectiveness of benralizumab in patients with severe asthma.
    Respir Res. 2021;22:163.
    PubMed     Abstract available


  22. LAMB D, De Sousa D, Quast K, Fundel-Clemens K, et al
    RORgammat inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma.
    Respir Res. 2021;22:158.
    PubMed     Abstract available


  23. PERTZOV B, Ronen M, Rosengarten D, Shitenberg D, et al
    Use of capnography for prediction of obstruction severity in non-intubated COPD and asthma patients.
    Respir Res. 2021;22:154.
    PubMed     Abstract available


  24. MORICHIKA D, Taniguchi A, Oda N, Fujii U, et al
    Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in mice.
    Respir Res. 2021;22:150.
    PubMed     Abstract available


  25. LIU MC, Chipps B, Munoz X, Devouassoux G, et al
    Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Respir Res. 2021;22:144.
    PubMed     Abstract available


  26. WANG T, Zhou Y, Kong N, Zhang J, et al
    Weight gain from early to middle adulthood increases the risk of incident asthma later in life in the United States: a retrospective cohort study.
    Respir Res. 2021;22:139.
    PubMed     Abstract available


  27. RAHERISON-SEMJEN C, Parrat E, Nocent-Eijnani C, Mangiapan G, et al
    FASE-CPHG Study: identification of asthma phenotypes in the French Severe Asthma Study using cluster analysis.
    Respir Res. 2021;22:136.
    PubMed     Abstract available


  28. GLOECKL R, Schneeberger T, Leitl D, Reinold T, et al
    Whole-body vibration training versus conventional balance training in patients with severe COPD-a randomized, controlled trial.
    Respir Res. 2021;22:138.
    PubMed     Abstract available


    April 2021
  29. HEALY C, Munoz-Wolf N, Strydom J, Faherty L, et al
    Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.
    Respir Res. 2021;22:133.
    PubMed     Abstract available


  30. KWOK WC, Ho JCM, Tam TCC, Ip MSM, et al
    Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications.
    Respir Res. 2021;22:132.
    PubMed     Abstract available


  31. SINGH D, Criner GJ, Dransfield MT, Halpin DMG, et al
    InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
    Respir Res. 2021;22:130.
    PubMed     Abstract available


  32. PRATTE KA, Curtis JL, Kechris K, Couper D, et al
    Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.
    Respir Res. 2021;22:127.
    PubMed     Abstract available


  33. CHEN A, Diaz-Soto MP, Sanmamed MF, Adams T, et al
    Single-cell characterization of a model of poly I:C-stimulated peripheral blood mononuclear cells in severe asthma.
    Respir Res. 2021;22:122.
    PubMed     Abstract available


  34. MAJORSKI DS, Magnet FS, Thilemann S, Schmoor C, et al
    Portable NIV for patients with moderate to severe COPD: two randomized crossover trials.
    Respir Res. 2021;22:123.
    PubMed     Abstract available


  35. ZHANG WZ, Hoffman KL, Schiffer KT, Oromendia C, et al
    Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.
    Respir Res. 2021;22:126.
    PubMed     Abstract available


  36. SINGH R, Belchamber KBR, Fenwick PS, Chana K, et al
    Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD.
    Respir Res. 2021;22:113.
    PubMed     Abstract available


  37. WORTH H, Criee CP, Vogelmeier CF, Kardos P, et al
    Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany.
    Respir Res. 2021;22:108.
    PubMed     Abstract available


  38. SADATSAFAVI M, Khakban A, Tavakoli H, Ehteshami-Afshar S, et al
    Trends in oral corticosteroids use in severe asthma: a 14-year population-based study.
    Respir Res. 2021;22:103.
    PubMed     Abstract available


  39. LI X, Noell G, Tabib T, Gregory AD, et al
    Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD.
    Respir Res. 2021;22:100.
    PubMed     Abstract available


    March 2021
  40. CHUBACHI S, Yamada Y, Yamada M, Yokoyama Y, et al
    Differences in airway lumen area between supine and upright computed tomography in patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:95.
    PubMed     Abstract available


  41. MACHADO FVC, Spruit MA, Groenen MTJ, Houben-Wilke S, et al
    Frequency and functional translation of low muscle mass in overweight and obese patients with COPD.
    Respir Res. 2021;22:93.
    PubMed     Abstract available


  42. PAN K, Lu J, Song Y
    Artesunate ameliorates cigarette smoke-induced airway remodelling via PPAR-gamma/TGF-beta1/Smad2/3 signalling pathway.
    Respir Res. 2021;22:91.
    PubMed     Abstract available


  43. ZHENG J, Baldi S, Zhao L, Li H, et al
    Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Respir Res. 2021;22:90.
    PubMed     Abstract available


  44. VAN ZELST CM, Kasteleyn MJ, van Noort EMJ, Rutten-van Molken MPMH, et al
    The impact of the involvement of a healthcare professional on the usage of an eHealth platform: a retrospective observational COPD study.
    Respir Res. 2021;22:88.
    PubMed     Abstract available


  45. PARK HJ, Kim SR, Kim S, Lee HS, et al
    Influence of government-driven quality assessment program on patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:87.
    PubMed     Abstract available


  46. SERRE J, Tanjeko AT, Mathyssen C, Vanherwegen AS, et al
    Enhanced lung inflammatory response in whole-body compared to nose-only cigarette smoke-exposed mice.
    Respir Res. 2021;22:86.
    PubMed     Abstract available


  47. BLERVAQUE L, Prefaut C, Forthin H, Maffre F, et al
    Efficacy of a long-term pulmonary rehabilitation maintenance program for COPD patients in a real-life setting: a 5-year cohort study.
    Respir Res. 2021;22:79.
    PubMed     Abstract available


  48. CAO Y, Xing Z, Long H, Huang Y, et al
    Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit.
    Respir Res. 2021;22:77.
    PubMed     Abstract available


  49. SHAHANGIAN K, Ngan DA, Chen HHR, Oh Y, et al
    IL-4Ralpha blockade reduces influenza-associated morbidity in a murine model of allergic asthma.
    Respir Res. 2021;22:75.
    PubMed     Abstract available


    February 2021
  50. PEROTIN JM, Polette M, Deslee G, Dormoy V, et al
    CiliOPD: a ciliopathy-associated COPD endotype.
    Respir Res. 2021;22:74.
    PubMed     Abstract available


  51. WU TD, Fawzy A, Kinney GL, Bon J, et al
    Metformin use and respiratory outcomes in asthma-COPD overlap.
    Respir Res. 2021;22:70.
    PubMed     Abstract available


  52. CALMES D, Huynen P, Paulus V, Henket M, et al
    Chronic infection with Chlamydia pneumoniae in asthma: a type-2 low infection related phenotype.
    Respir Res. 2021;22:72.
    PubMed     Abstract available


  53. LI LY, Yan TS, Yang J, Li YQ, et al
    Impulse oscillometry for detection of small airway dysfunction in subjects with chronic respiratory symptoms and preserved pulmonary function.
    Respir Res. 2021;22:68.
    PubMed     Abstract available


  54. MALVISI L, Taddei L, Yarraguntla A, Wilkinson TMA, et al
    Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints.
    Respir Res. 2021;22:67.
    PubMed     Abstract available


  55. GULEA C, Zakeri R, Alderman V, Morgan A, et al
    Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.
    Respir Res. 2021;22:64.
    PubMed     Abstract available


  56. YANG N, Singhera GK, Yan YX, Pieper MP, et al
    Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells.
    Respir Res. 2021;22:65.
    PubMed     Abstract available


  57. BEKAERT S, Rocks N, Vanwinge C, Noel A, et al
    Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11-CCR3 pathway.
    Respir Res. 2021;22:61.
    PubMed     Abstract available


  58. PISON C, Shah PL, Slebos DJ, Ninane V, et al
    Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes.
    Respir Res. 2021;22:62.
    PubMed     Abstract available


  59. SAITO T, Ichikawa T, Numakura T, Yamada M, et al
    PGC-1alpha regulates airway epithelial barrier dysfunction induced by house dust mite.
    Respir Res. 2021;22:63.
    PubMed     Abstract available


  60. CHEN W, Sadatsafavi M, FitzGerald JM, Lynd LD, et al
    Gender modifies the effect of body mass index on lung function decline in mild-to-moderate COPD patients: a pooled analysis.
    Respir Res. 2021;22:59.
    PubMed     Abstract available


  61. CORDOBA-LANUS E, Cazorla-Rivero S, Garcia-Bello MA, Mayato D, et al
    Telomere length dynamics over 10-years and related outcomes in patients with COPD.
    Respir Res. 2021;22:56.
    PubMed     Abstract available


  62. EHTESHAMI-AFSHAR S, Crothers K, Rodwin B, Bade B, et al
    Does pulmonary subspecialty referral from primary care affect the adherence to vaccination recommendations in COPD patients?
    Respir Res. 2021;22:50.
    PubMed     Abstract available


  63. SAVRAN O, Godtfredsen N, Sorensen T, Jensen C, et al
    COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?
    Respir Res. 2021;22:54.
    PubMed     Abstract available


  64. KANG J, Lee JS, Lee SW, Lee JB, et al
    Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials.
    Respir Res. 2021;22:55.
    PubMed     Abstract available


  65. KERMANI NZ, Song WJ, Badi Y, Versi A, et al
    Correction to: Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma.
    Respir Res. 2021;22:47.
    PubMed    


  66. VAN DEN BERG MPM, Nijboer-Brinksma S, Bos IST, van den Berge M, et al
    The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs.
    Respir Res. 2021;22:48.
    PubMed     Abstract available


  67. WANG Y, Liao K, Liu B, Niu C, et al
    GITRL on dendritic cells aggravates house dust mite-induced airway inflammation and airway hyperresponsiveness by modulating CD4(+) T cell differentiation.
    Respir Res. 2021;22:46.
    PubMed     Abstract available


  68. HU Y, Chen Y, Liu S, Jiang F, et al
    Breastfeeding duration modified the effects of neonatal and familial risk factors on childhood asthma and allergy: a population-based study.
    Respir Res. 2021;22:41.
    PubMed     Abstract available


  69. KIM J, Kim B, Bak SH, Oh YM, et al
    A comparative study of chest CT findings regarding the effects of regional dust exposure on patients with COPD living in urban areas and rural areas near cement plants.
    Respir Res. 2021;22:43.
    PubMed     Abstract available


  70. SONG Q, Chen P, Liu XM
    The role of cigarette smoke-induced pulmonary vascular endothelial cell apoptosis in COPD.
    Respir Res. 2021;22:39.
    PubMed     Abstract available


  71. CALLE RUBIO M, Rodriguez Hermosa JL, de Torres JP, Marin JM, et al
    COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort.
    Respir Res. 2021;22:36.
    PubMed     Abstract available


  72. TAKEUCHI H, Hasan SMT, Zaman K, Takanashi S, et al
    Impact of Haemophilus influenzae type b combination vaccination on asthma symptoms and pneumonia in 5-year-old children in rural Bangladesh: a longitudinal study and comparison with a previous cross-sectional study.
    Respir Res. 2021;22:35.
    PubMed     Abstract available


  73. GALDI F, Pedone C, McGee CA, George M, et al
    Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study.
    Respir Res. 2021;22:30.
    PubMed     Abstract available


    January 2021
  74. FENG Z, Wang J, Xie Y, Li J, et al
    Effects of exercise-based pulmonary rehabilitation on adults with asthma: a systematic review and meta-analysis.
    Respir Res. 2021;22:33.
    PubMed     Abstract available


  75. MAGNUSSEN H, Lucas S, Lapperre T, Quint JK, et al
    Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study.
    Respir Res. 2021;22:25.
    PubMed     Abstract available


  76. LAM R, Kwon S, Riggs J, Sunseri M, et al
    Dietary phenotype and advanced glycation end-products predict WTC-obstructive airways disease: a longitudinal observational study.
    Respir Res. 2021;22:19.
    PubMed     Abstract available


  77. SHIRAHATA T, Sato H, Yogi S, Inoue K, et al
    The product of trunk muscle area and density on the CT image is a good indicator of energy expenditure in patients with or at risk for COPD.
    Respir Res. 2021;22:18.
    PubMed     Abstract available


  78. SCHLEICH F, Graff S, Guissard F, Henket M, et al
    Asthma in elderly is characterized by increased sputum neutrophils, lower airway caliber variability and air trapping.
    Respir Res. 2021;22:15.
    PubMed     Abstract available


  79. LEMAIRE F, Audonnet S, Perotin JM, Gaudry P, et al
    The elastin peptide VGVAPG increases CD4(+) T-cell IL-4 production in patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:14.
    PubMed     Abstract available


  80. KERMANI NZ, Song WJ, Badi Y, Versi A, et al
    Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma.
    Respir Res. 2021;22:10.
    PubMed     Abstract available


  81. BAGGE K, Sivapalan P, Eklof J, Hertz FB, et al
    Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid-data from 43,636 outpatients.
    Respir Res. 2021;22:11.
    PubMed     Abstract available


  82. MAO X, Liang C, Niu H, Dong F, et al
    Outcomes associated with comorbid diabetes among patients with COPD exacerbation: findings from the ACURE registry.
    Respir Res. 2021;22:7.
    PubMed     Abstract available


    November 2020
  83. ALNAJEM A, Redha A, Alroumi D, Alshammasi A, et al
    Use of electronic cigarettes and secondhand exposure to their aerosols are associated with asthma symptoms among adolescents: a cross-sectional study.
    Respir Res. 2020;21:300.
    PubMed     Abstract available


    October 2020
  84. SINGH D, Virchow JC, Canonica GW, Vele A, et al
    Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
    Respir Res. 2020;21:285.
    PubMed     Abstract available


  85. ABDO M, Watz H, Veith V, Kirsten AM, et al
    Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
    Respir Res. 2020;21:278.
    PubMed     Abstract available


  86. MENZIES-GOW A, Ponnarambil S, Downie J, Bowen K, et al
    DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Respir Res. 2020;21:279.
    PubMed     Abstract available


  87. NEMOTO M, Nei Y, Bartholmai B, Yoshida K, et al
    Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study.
    Respir Res. 2020;21:275.
    PubMed     Abstract available


  88. GROTH EE, Weber M, Bahmer T, Pedersen F, et al
    Exploration of the sputum methylome and omics deconvolution by quadratic programming in molecular profiling of asthma and COPD: the road to sputum omics 2.0.
    Respir Res. 2020;21:274.
    PubMed     Abstract available


  89. MENZIES-GOW A, Wechsler ME, Brightling CE
    Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Respir Res. 2020;21:268.
    PubMed     Abstract available


  90. MENZIES-GOW A, Colice G, Griffiths JM, Almqvist G, et al
    NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Respir Res. 2020;21:266.
    PubMed     Abstract available


  91. WECHSLER ME, Colice G, Griffiths JM, Almqvist G, et al
    SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Respir Res. 2020;21:264.
    PubMed     Abstract available


  92. EMSON C, Diver S, Chachi L, Megally A, et al
    CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
    Respir Res. 2020;21:265.
    PubMed     Abstract available


    September 2020
  93. MATUSIAK M, Schurch CM
    Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics.
    Respir Res. 2020;21:252.
    PubMed     Abstract available


  94. MILLER D, Vaidya S, Jauernig J, Ethell B, et al
    Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Respir Res. 2020;21:248.
    PubMed     Abstract available


    June 2020
  95. ESTEBAN C, Arostegui I, Aramburu A, Moraza J, et al
    Predictive factors over time of health-related quality of life in COPD patients.
    Respir Res. 2020;21:138.
    PubMed     Abstract available


  96. DAY NC, Kumar S, Criner G, Dransfield M, et al
    Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Respir Res. 2020;21:139.
    PubMed     Abstract available


  97. MATHYSSEN C, Aelbrecht C, Serre J, Everaerts S, et al
    Local expression profiles of vitamin D-related genes in airways of COPD patients.
    Respir Res. 2020;21:137.
    PubMed     Abstract available


  98. SINGH D, Criner GJ, Naya I, Jones PW, et al
    Measuring disease activity in COPD: is clinically important deterioration the answer?
    Respir Res. 2020;21:134.
    PubMed     Abstract available


    May 2020
  99. KIM T, Cho HB, Kim WJ, Lee CH, et al
    Quantitative CT-based structural alterations of segmental airways in cement dust-exposed subjects.
    Respir Res. 2020;21:133.
    PubMed     Abstract available


  100. FERGUSON GT, Brown N, Compton C, Corbridge TC, et al
    Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Respir Res. 2020;21:131.
    PubMed     Abstract available


  101. MARTINEZ FJ, Lipworth BJ, Rabe KF, Collier DJ, et al
    Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Respir Res. 2020;21:128.
    PubMed     Abstract available


  102. RAYMAKERS A, Sin DD, Sadatsafavi M, FitzGerald JM, et al
    Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study.
    Respir Res. 2020;21:118.
    PubMed     Abstract available


  103. GREULICH T, Tuffers J, Mager S, Eder A, et al
    High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis.
    Respir Res. 2020;21:106.
    PubMed     Abstract available


  104. WILSON AC, Kumar PL, Lee S, Parker MM, et al
    Heme metabolism genes Downregulated in COPD Cachexia.
    Respir Res. 2020;21:100.
    PubMed     Abstract available


    April 2020
  105. MACKAY AJ, Kostikas K, Roche N, Frent SM, et al
    Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
    Respir Res. 2020;21:93.
    PubMed     Abstract available


  106. SCHERR A, Schumann DM, Karakioulaki M, Franchetti L, et al
    Endothelial dysfunction is not a predictor of outcome in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:90.
    PubMed     Abstract available


  107. DING Y, Yang Y, Li Q, Feng Q, et al
    The correlation between CYP4F2 variants and chronic obstructive pulmonary disease risk in Hainan Han population.
    Respir Res. 2020;21:86.
    PubMed     Abstract available


  108. TUNG LF, Shen SY, Shih HH, Chen YT, et al
    Effect of high-flow nasal therapy during early pulmonary rehabilitation in patients with severe AECOPD: a randomized controlled study.
    Respir Res. 2020;21:84.
    PubMed     Abstract available


    March 2020
  109. LANGTON D, Bennetts K, Noble P, Plummer V, et al
    Bronchial thermoplasty reduces airway resistance.
    Respir Res. 2020;21:76.
    PubMed     Abstract available


  110. ZHENG J, Xu JF, Jenkins M, Assam PN, et al
    Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naive patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.
    Respir Res. 2020;21:69.
    PubMed     Abstract available


  111. GAO S, Chen J, Xie J, Wang J, et al
    The effects of BAFF on T lymphocytes in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:66.
    PubMed     Abstract available


  112. MAGDY DM, Metwally A
    Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic hypercapnic respiratory failure: a randomized trial.
    Respir Res. 2020;21:64.
    PubMed     Abstract available


  113. PASCUAL-GUARDIA S, Ataya M, Ramirez-Martinez I, Yelamos J, et al
    Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients.
    Respir Res. 2020;21:63.
    PubMed     Abstract available


    February 2020
  114. AXSON EL, Ragutheeswaran K, Sundaram V, Bloom CI, et al
    Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis.
    Respir Res. 2020;21:54.
    PubMed     Abstract available


  115. GOORSENBERG AWM, d'Hooghe JNS, Slats AM, van den Aardweg JG, et al
    Resistance of the respiratory system measured with forced oscillation technique (FOT) correlates with bronchial thermoplasty response.
    Respir Res. 2020;21:52.
    PubMed     Abstract available


  116. SALVI SS, Brashier BB, Londhe J, Pyasi K, et al
    Phenotypic comparison between smoking and non-smoking chronic obstructive pulmonary disease.
    Respir Res. 2020;21:50.
    PubMed     Abstract available


  117. XIE M, Liu X, Cao X, Guo M, et al
    Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017.
    Respir Res. 2020;21:49.
    PubMed     Abstract available


  118. SINGH D, Martinez FJ, Watz H, Bengtsson T, et al
    A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
    Respir Res. 2020;21:47.
    PubMed     Abstract available


  119. TAM A, Tanabe N, Churg A, Wright JL, et al
    Sex differences in lymphoid follicles in COPD airways.
    Respir Res. 2020;21:46.
    PubMed     Abstract available


  120. PADBERG I, Schneider A, Rohmann JL, Kelley SW, et al
    Impact of COPD and anemia on motor and cognitive performance in the general older population: results from the English longitudinal study of ageing.
    Respir Res. 2020;21:40.
    PubMed     Abstract available


    January 2020
  121. FRATTA PASINI AM, Stranieri C, Ferrari M, Garbin U, et al
    Oxidative stress and Nrf2 expression in peripheral blood mononuclear cells derived from COPD patients: an observational longitudinal study.
    Respir Res. 2020;21:37.
    PubMed     Abstract available


  122. TANNO A, Fujino N, Yamada M, Sugiura H, et al
    Decreased expression of a phagocytic receptor Siglec-1 on alveolar macrophages in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:30.
    PubMed     Abstract available


  123. SIEVI NA, Brack T, Brutsche MH, Frey M, et al
    "Can do, don't do" are not the lazy ones: a longitudinal study on physical functioning in patients with COPD.
    Respir Res. 2020;21:27.
    PubMed     Abstract available


  124. DIVO MJ, DePietro MR, Horton JR, Maguire CA, et al
    Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial.
    Respir Res. 2020;21:26.
    PubMed     Abstract available


  125. KAHNERT K, Fohrenbach M, Lucke T, Alter P, et al
    The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET.
    Respir Res. 2020;21:28.
    PubMed     Abstract available


  126. JIANG JX, Shen HJ, Guan Y, Jia YL, et al
    ZDHXB-101 (3',5-Diallyl-2, 4'-dihydroxy-[1,1'-biphen-yl]-3,5'-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator
    Respir Res. 2020;21:22.
    PubMed     Abstract available


  127. PEREA L, Rodrigo-Troyano A, Canto E, Dominguez-Alvarez M, et al
    Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity.
    Respir Res. 2020;21:21.
    PubMed     Abstract available


  128. LONG GH, Southworth T, Kolsum U, Donaldson GC, et al
    The stability of blood Eosinophils in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:15.
    PubMed     Abstract available


  129. BAFADHEL M, Singh D, Jenkins C, Peterson S, et al
    Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis.
    Respir Res. 2020;21:17.
    PubMed     Abstract available


  130. WALSCHER J, Gross B, Morisset J, Johannson KA, et al
    Comorbidities and survival in patients with chronic hypersensitivity pneumonitis.
    Respir Res. 2020;21:12.
    PubMed     Abstract available


  131. HARTLEY BF, Barnes NC, Lettis S, Compton CH, et al
    Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis.
    Respir Res. 2020;21:5.
    PubMed     Abstract available


  132. HARRIES TH, Rowland V, Corrigan CJ, Marshall IJ, et al
    Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.
    Respir Res. 2020;21:3.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Obstructive Lung Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: